Jan 21 2016
Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing testing for cancer patients today announced that it has entered into a contractual agreement with UnitedHealthcare for coverage of PCDx™.
PCDx™ is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patient's tumor's DNA, RNA & Protein.
Dr. Robert Penny, MD, PhD, CEO of Paradigm, stated, "We continue to make excellent progress in our discussions with provider networks to ensure our best-in-class NGS test is available to the millions of Americans who are suffering with cancer. With this contract, millions of patients and their treating clinicians will have access to our leading oncology testing service and make possible more informed and individually tailored treatment strategies."
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery